On an expansion spree, German manufacturer Sartorius makes $500M+ purchase of cell culture media player
Over the past year, the German-based life science group Sartorius has made several moves to grow the company in the cell and gene therapy space, and its latest move sees the company continuing that track as it is committing to a nine-figure deal to bring UK-based Albumedix under its wing.
The deal will have Sartorius acquiring 100% of the company from private investors for £415 million, or around $502 million. Albumedix, based in the city of Nottingham, UK, is a manufacturer of albumin-based products. Albumin serves as a major ingredient in cell culture media and is used as an animal-free additive in the manufacturing of vaccines, cell therapies and viral therapies. The transaction is expected to close before the end of Q3 of 2022.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters